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Eosinophil granular protein deposits have been demonstrated 
in lesional atopic dermatitis skin. This suggests active tissue 
infiltration of eosinophils. To find an explanation for the 
tissue influx of eosinophils, eosinophil migration was studied 
in vitro by means of a microchemotaxis assay. Eosinophils 
from the circulation of patients with atopic dermatitis 
showed an altered capacity to respond to chemotactic stimuli 
in vitro compared with eosinophils from healthy donors. Eo-
sinophils from patients with atopic dermatitis had signifi-
cantly increased migratory responses toward dose ranges of 
N-formyl-methionyl-leucyl-phenylalanine, neutrophil-ac-
tivating factor, platelet-activ~tin~ .factor, ~nd platelet factor 
4. Eosinophils from normal llldlviduais did not respond to 
N-formyl-methionyl-leucyl-phenylalanine and neutrophil-
activating factor and responded only slightly to platelet fac-
tor 4. The migratory responses toward tumor necrosis factor-
a and complement factor CSa were identical in both groups. 
I ncreased blood eosinophilia is regularly observed in patients with atopic dermatitis [1]. Increased serum eosinophil cat-ionic protein levels in these patients reflect activation of eo-sinophils [2]. In lesional atopic dermatitis skin, dermal depos-its of major basic protein were demonstrated, which suggests 
eosinophil degranulation [3]. Furthermore, eosinophils appear in 
the skin of patients with atopic dermatitis after a patch-test reaction 
with aeroallergens [4]. These patch-test reactions induce a macro-
scopically and microscopically almost identical skin reaction, as ob-
served in lesional atopic dermatitis skin [5,6]. Analysis of the cellular 
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Abbreviations: 
CSa: complement fragment CSa 
FMLP: N-formyl-methionyl-leucyl-phenylalanine 
GM-CSF: granulocyte/macrophage-colony-stimulating factor 
HSA: human serum albumin 
Ig: immunoglobulin 
IL: interleukin 
NAF /IL-8: neutrophil activating-factor/interleukin-8 
PAF: platelet-activating factor 
PF4: platelet factor 4 
TNF: tumor necrosis factor 
Interleukin-5, an eosinophil-selective cytokine, is a strong 
modulator of the migratory responses to these chemotaxins 
in eosinophils from normal donors. A migratory response 
toward N-formyl-methionyl-leucyl-phenylalanine and neu-
trophil-activating factor was induced by interleukin-5, 
whereas the migratory response toward platelet-activating 
factor and platelet factor 4 was markedly potentiated. In con-
tr~st, th~ response to complement fragment CSa was only 
shghtly lllfluenced. Our findings indicate that the increased 
mig~atory res~o~siveness. of eosinophils .from patients with 
atopIc dermatitis to vanous chemotaxllls reflects in vivo 
"priming" of eosinophils, presumably by circulating cyto-
kin~s such as int~rleukin-S. This in vivo "priming" is not 
optimal because It can be further potentiated by renewed 
contact with interleukin-S.] Invest DermatoI100:137-142, 
1993 
infiltrate in the dermis and epidermis showed active infiltration ofT 
lymphocytes. and eosi~lOphils atthe site of allergen application [5 -
7]. Further histochemical analYSIS of the infiltrated eosinophils dem-
onstrated that these cells were in an activated state and had released 
part ?f their granular conte~lts, in particular eosinophil cationic 
protell1 [5]. The eosll1ophds disappeared from the dermis and epider-
mis 72 h after the patcl? test, together with the macroscopically 
obser:ed eczematous leSIOn [5]. Thereafter, the eosinophil-derived 
depOSits remall1ed. Careful analysis of the cellular infiltrates of the 
patch-test reactio~ indicated that other than eosinophils, no other 
granulocytes had ll1filtrated the skin [5]. Therefore these observa-
tions stimulated us to study eosinophil migration in more detail. 
111 vi~ro investigati~ns indicate that eosinophils do respond to the 
followll1g chemotaxll1s: platelet activating factor (PAF), comple-
ment fragment C5a, and leukotriene B4 [8,9]; however, these che-
motaxinsare not selective for eosinophils because they also attract 
ne~troph.tls. It was recently shown that interleukin (IL)-S acts as an 
eoslll~pI1l1-~elecuve chemotaxin [10,11] and promotes the adhesion 
of eoslllo£lllls, but not of neutrophils, to human endothelial mono-
layers [12J: We were able to show that eosinophils also do respond 
chemotactically to relatively high concentrations of the cytokines 
IL-3 and granulocyte/ macrophage - colony-stimulating factor 
(GM-CSF). At relatively low concentrations these cytokines are 
capable of inducing migratory responsiveness toward N-formyl-
methionyl- leucyl-phenylalanine (FMLP) and neutrophil-activat-
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ing factor (NAF)/IL-8 in eosinophils from normal, healthy individ-
uals [13] . . 
In atopic dermatitis there is a clear dysfunctlOn of T cells [14]. 
Recently, activated T cells could be demonstrate~ m the circulation 
of patients with atopic dermatitis [15] . These actlvated T cells were 
capable of spontaneously secreting the cytokines IL-3, IL-5, and 
GM-CSF [15,16] . T hese cytokines are important modulators of 
eosinophil function such as migration[13]. . .. 
We have investigated whether eosmoplllls from patients with 
atopic dermatitis showed a ~iffere~t migratory response ~o a. v~riety 
of chemotaxins compared with eosmoplllls from normal mdividuals 
and whether priming by IL-5 could explain the changed responsive-
ness. 
MATERIALS AND METHODS 
Subjects All patients (10 women and 16 men, ages between 17 
and 48 years) participating in t.his study. had atopi~ dermatitis as 
classified according to the cntena of Hal1lfin and RaJka [17] . They 
were all allergic to three or more different allergens, had positive 
skin reactions to these allergens, elevated total immunoglobulin (Ig) 
E levels, and positive radio allergo sorbent tests (RASTs) for the 
relevant allergens. The patients had not taken oral steroids for at 
least 2 weeks before the study. They were treated only with small 
amounts of topically applied steroids. All other therapy was stopped 
at least 2 weeks before the study. At the time of blood collection 
most patients had mild to moderate eczema; locally active lesions 
were present. All patients had elevated blood eosinophil levels 
(> 8%). The normal, healthy volunteers were not allergic, had nor-
mal blood eosinophil levels, and did not take any medication. All 
participating individuals gave their informed consent. 
Reagents PAF (1-Q-hexadecyl-2-acetyl-sn-glycero-3-phosphor-
ylcholine) was purchased from Bache~ Feinchemicalien AG (Bu-
bendorf, Switzerland) . Human recombmant C5a, FMLP, and plate-
let factor (PF)4 were purchased from Sigma (St. Louis, MO). 
Tumor necrosis factor (TNF)-Q was from Cetus Corp. (Emeryville, 
CA). Ficoll-paque and Percoll were obtained from Pharmacia 
(U ppsala, Swe~en) . All expenment~ were carried out in Geys' bal-
anced salt solutlOn supplemented with 1.5 mM CaCI2 , heparin (10 
IU/ml), 5 mM glucose, and 1.0% human serum albumin (HSA) 
(wt/vol) . 
cytokines Recombinant hu~an IL-5 .(4 X lOs U/ml) was a kind 
gift of Dr. C.J. Sanderson (l':!atlOnal Institute for Medical Research, 
London, U.K.). The molanty of thiS IL-5 preparation was deter-
mined by comparison of its potency with commercially available 
rhIL-5 (Amersham, Buckinghamshire, U .K.; 106 U /mg). Recombi-
nant human NAF/IL-8 (1.2 J,lg/ml) was a kind gift from Dr. I. 
Lindley (Sandoz Forschungsinstitut GmbH, Vienna, Austria) . Stock 
solutions of the cytokines were prepared in phosphate-buffered sa-
line supplemented with 0.1 % purified HSA and were stored at 
-70°C until use. 
Cell Isolation Blood was obtained from healthy volunteers or 
from patients with atopic dermatitis. Eosinophils from the blood of 
normal donors were isolated from the buffy coat of 500 mlofblood, 
and eosinophils from the patients were isolated from 40 ml of blood 
anticoagulated with 0.4% (wt/vol) trisodium citrate (pH 7.4), as 
described previously [1 8]. Briefly, mononuclear cells were removed 
by separation of blood over isotonic Ficoll Paque (1.077 g/ml, pH 
7.4). After isotonic lysis of the erythrocytes in an ice-cold solution 
containing 155 mM NH4CI, 10 mM KHC03 , and 0.1 mM ethy-
lenediaminetetraacetic acid (pH 7.2), the granulocytes were washed 
and resuspended in RPMI supplemented with HSA (1 % wt/vol) 
and incubated 30 min at 37°C to restore initial densities of the cells. 
After this incubation period, the cells were washed and resuspended 
in phosphate-buffered saline supplemented with HSA (1 % wt/vol) 
and trisodium citrate (0.4% wt/vol). After pre-incubation of the 
cells for 5 min at 3rC, FMLP (10 nM) was added to the cell 
suspension, and the incubation was continued for 10 min at 37°C 
before 1 ml of cell suspension was layered on 4 ml of an isotonic 
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Percoll solution (density 1.082 g/ml) . To prevent contamination of 
the cells with cell debris and remaining erythrocytes, 1 ml of Per-
coil (density 1.100 g/ml) was brought under the Percoll1.082 g/ml 
solution. After centrifugation (20 min, 1000 X g maximum, room 
temperature), the eosinophils were collected from the interface. 
The eosinophils were washed and resuspended in Geys' buffer and 
kept at room temperature until use. The FMLP treatment does not 
influence eosinophil function, as is extensively documented else-
where [13 ,18 - 20]. The purity of the cells was always over 90%, and 
the recovery ranged from 40% to 70%. For comparison, eosinophils 
were also isolated using the immunomagnetic bead method, as de-
scribed by Hansel et af [21] . Briefly , Immunomagnetic beads (Dynal 
Beads, Dyrial A.S., Oslo, Norway) were coated with a monoclonal 
antibody against CD 16 (CLB FcR gran 1; Central Laboratory of the 
Red Cross Blood Transfusion, Amsterdam, The Netherlands) . 
These coated beads were coincubated at 4 ° C for 20 min with the 
granulocyte preparation (107 cells/ml) in a ratio of 1: 4 (cells/ 
beads). The neutrophils were subsequently removed by a magnetic 
particle concentrator (MPCTH_l; Dynal A.S.) . 
Migration Assay Migration was measured with a modified Boy-
den chamber assay using a 48-well microchemotaxis chamber 
(Neuroprobe, Cabin John, MD). Chemotaxins or Geys' buffer 
(30 J,ll) was placed in the lower compartments. Two filters (cellu-
lose nitrate) were placed between the lower and the upper compart-
ments. The lower filter had a pore width of 0.45 J,lm (Millipore type 
HA; Millipore Corporation, Bedford, MA), and the upper filter had 
a pore width of 8 J,lm (Sartorius, SM 113; Sartorius AG, Gottingen, 
Germany) . Before use, the filters were soaked in Geys' buffer. Puri-
fied eosinophils, pre-incubated with the tested cytokine (IL-5) or 
with Geys' buffer for 30 min at 37 °C, were placed in the upper 
compartment (25 J,ll of 5 X 106 cells/ml). The chemotaxis 
chambers were subsequently incubated for 2.5 h at 3rC unless 
otherwise stated. Hereafter, the upper filters were removed, fixed in 
butanol/ethanol (20%/80%, v Iv) for 10 min and stained with 
Weigert solution [1 % hematoxylin (v Iv) in 95% ethanol (v Iv) and 
an acidic FeCl3 solution (70 mM) mixed in a volume ratio of 1 : 1]. 
The filters were dehydrated with ethanol, made transparant with 
xylene, and fixed upside down. The number of cells per 10 high-
power fields was determined with light microscopy (magnification 
X 400). In this way, the number of cells that had passed the upper 
filter was determined. 
Statistical Analysis All data are presented as mean ± SD. The 
Student t test for paired or unpaired data was applied; p values < 
0.05 were considered significant. 
RESULTS 
Migratory Responsiveness of Eosinophils from the Circula-
tion of Patients with Atopic Dermatitis and Normal Individ-
uals Toward FMLP, NAF/IL-8, PAF, PF4, TNF-Q, and 
CSa As is depicted in Fig 1, the eosinophils from patients with 
atopic dermatitis showed significantly increased migratory re-
sponses toward dose ranges of FMLP, NAF/IL-8, PAF, and PF4 
compared with eosinophils from normal individuals. These data 
showed that FMLP and NAF/IL-8 were not chemotactic toward 
eosinophils from normal individuals. PF4 had only weak chemotac-
tic activity on eosinophils from normal individuals. In contrast, 
eosinophils from patients with atopic dermatitis showed significant 
migratory responsiveness toward these chemotaxins. In the case of 
the PAF-induced chemotaxis, a leftward shift in the responsiveness 
was present. Eosinophils from patients with atopic dermatitis 
showed a migratory response to PAF at concentrations approxi-
mately 10- 11 M. This PAF concentration is not chemotactic for 
eosinophils from normal individuals. These data are strongly sug-
gestive for "itl vivo" priming of the eosinophils from patients with 
atopic dermatitis [13J. 
In contrast to the FMLP-, NAF/IL-8-, PAF-, and PF4-induced 
migratory responses, the TNF-Q- and the C5a-induced migratory 
responses of eosinophils from patients with atopic dermatitis and 
normal individuals are completely identical. 
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Figure 1. Migration of eo sino phi Is isola~e.d from normal, healthy indi~d­
uals~) and patients WIth atopIc dermatitis (0) toward (A) FMLP (10 10_ 
10-S M); (B) NAF/IL-8 (10- 1°-10-SM); (C) PAF (10- 12 -1O- 6 M); (D) 
PF4 (10- 12 -1O- s M); (E) TNF-a (10- 12-1O-s M); and (F) C5a (10- 12 -
10-7 M), with Geys' buffer as a control. Mean values ± SO are presented 
for seven to eight experiments for FMLP, P AF, and C5a and five different 
experiments for NAF /IL-8, PF4, and TNF-a. • Values differed sigrUfi-
cantly from those obtained from the norma\, healthy individuals (p < 
0 .05; unpaired Student t test). hp£' high-powered fields . 
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Table II. Influence of Pre-incubating Eosinophils with Buffer 
or a Dose Range of IL-S on the Chemotaxin-induced Migratory 
Response of Eosinophils (in Cells per 10 High-Power Fields) 
from Normal Individuals· 
-log[IL-5] 
Chemotaxin Buffer 11 10 9 8 
FMLP 22± 7 70 ± 26 72 ± 37 98 ± 37 87 ± 30 
(10nM) 
NAF/'L-8 22 ± 7 67 ± 30 72 ± 37 74 ± 15 107 ± 50 
(10nM) 
PAF (1 nM) 25 ± 8 81 ± 30 NO 130 ± 14 NO 
PF4 (1 nM) 17 ± 5 78 ± 24 NO 128 ± 56 NO 
C5a (10 nM) 25 ± 8 180 ± 34 NO 200 ± 40 NO 
• Preincubation was performed for 30 min at 37°C. Mean values ± 50 for n = 4 or 
5 experiments are presented. All values obtained after preincubation with lL-5 
differed significantly from the buffer value (p < 0.05; paired Student t test) (for 
techttical details, see Materials atld Methods); NO, not done. 
Eosinophils from patients with atopic dermatitis and normal indi-
viduals isolated by the two different methods described ([18 ,21]; see 
also Matenals and Methods) responded completely identically to 
the chemoattractants used here, as shown in Table 1. The results 
presented in Table I indicate that the isolation of eosinophils from 
both normal mdlvlduals and patients with atopic dermatitis are 
equally influenced by treatment with FMLP or m agnetic beads with 
respect to the responses studied here. 
Influence ofIL-5 on the FMLP-. NAF /IL-S-. P AF-. and PF4-
Induced Migratory Response of Isolated Eosinophils from 
Normal Individuals. In Fig 1 it is shown that the FMLP-, NAF/ 
IL-8-, P~F-, an~ PF4-l11d';l~ed m!gration of eosinophils from pa-
tients with atopic dermatitis IS Significantly increased compared 
with responses of eosl11ophds from normal individuals. We investi-
gated whether priming of eosinophils from normal individuals with 
IL-S in vitro resulted in a similar effect. The results are shown in 
Table II. Pre-incubation of eosinophils from normal individuals 
with concentration ranges ofIL-S indeed induced significant migra-
tory responsiveness toward FMLP and NAF/ IL-8, whereas the re-
sponses to PAF and PF4 were considerably enhanced. The kinetics 
of the migratory responses after this it/vitro pre-treatment with IL-S 
were alm~st similar to those o?served in eosinophils from patients 
with atopic dermatitis. IL-S pnml11g was irreversible because wash-
Table I. Comparison of Migratory Responses (in Cells per 10 hpf) of Eosinophils from the Circulation of Normal Individuals and 
Patients with AtopiC Dermatitis Isolated by the FMLP Method (A) and the Magnetic Bead Method (B)· 
-log[Chemotaxinj 
Subjects and 11 10 9 Isolation Method Chemotaxin n 8 7 
N ormals 33 (6) 
A PAF 6 30 (6) 30 (7) 39 (10) 71 (12) 
B PAF 6 36 (7) 36 (7) 44 (8) 57 (10) 100 (18) 
Atopic Dermatitis 45 (13) 48 (15) 54 (15) A PAF 8 87 (1 5) 149 (23) 
B PAF 3 31 (10) 39 (10) 47 (11) 64 (10) 153 (1 7) 
Normals 
A FMLP 12 NO 15 (6) 17 (4) 30 (8) NO 
B FMLP 3 NO 15 (5) 16 (6) 25 (7) NO 
Atopic dermatitis 
NO 67 (30) 60 (25) A FMLP 5 59 (25) NO 
B FMLP 3 NO 118 (42) 55 (22) 58 (26) NO 
Normal 
A NAF/IL-8 6 ND 20 (6) 22 (6) 24 (7) NO 
B NAF/IL-8 6 NO NO NO 24 (8) NO 
Atopic dermatitis NO 55 (9) 57 (11) A NAF/IL-8 5 47 (18) NO 
B NAF/IL-8 3 NO 44 (14) 25 (20) 47 (10) NO 
• Results are expressed as mean values (±SO). None of the values presented obtained by method A differed significantly from those obtained by method B (unpaired Student 
t test). In these experiments, the blank control values were always approximately 20 cells/ IO high-power fields (hpf); NO, not done. 
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ing of the cells with cytokine-free buffer did not abrogate priming 
(data not shown). To show that the above effects. could be specifi-
cally ascribed to IL-5, thes~ effects we:e evaluated m the presence of 
a neutralizing antibody dIrected agamst IL-5 (400 U/ml of IL-5 
were neutralized by anti-hu-IL-5, 16 f1g/ml; the antibody was a 
kind gift of Dr. J. Tavernier, Roche, Ghent, BelglU~). W~en thIs 
antibody was added together with IL-5 to the eosm~plllls from 
normal individuals, the "priming" effect for the PAF-mduced re-
sponse ([PAF] = 1 nM) could be blocked for 87% ± 10% (mean ± 
SD; n = 4). 
Influence of IL-5 on the P AF- and C5a-Induced Migratory 
Response of Isolated Eosinophils from Patients w.ith Atopic 
Dermatitis and Normal Individuals Because IL-5 IS capable of 
"priming" eosinophils from normal individuals ~o respot;d more 
strongly to certain chemotaxins (e.g., ~AF) a.nd to mduce mlgra~ory 
responses to others (e.g., FMLP), .we mvestl.g~ted whether eosmo-
hils from patients with atopIc dermatltls could be further 
R rimed" in their response to PAF and C5a by IL-5 treatment 
(&L-5] = 1 nM). Indeed, the. responses of these e.os~nophils were 
potentiated by IL-5, and the m.cre~s~ was almost SImIlar compa~ed 
with eosinophils from normal mdlvlduals after pre-treatment wIth 
IL-5 (Fig 2A). In the case of .C5a-induced migration, only a small 
potentiation was observed (FIg 2B). 
DISCUSSION 
In this report we have shown t~at eos.in.ophils from the.circulation 
of patients with atopic dermatlt1s exhIbIt potentiated Imgratory re-
sponses toward FMLP, NAF/IL-8, PAF: and PF4 compared with 
eosinophils from normal d.onors: T!le mIgratory responses toward 
TNF-a and C5a did not dtffer slgmficantly. Recently, we demon-
strated that IL-3 and GM-CSF at picomolar concentrations are capa-
ble of increasing the migratory responses of eosinophils from nor-
mal individuals toward P AF and leukotriene B4 but not to C5a [13]. 
On the other hand, pre-treatment with these eytokines is essential 
for migratory responses toward NAF/IL-8 and FMLP. Here, we 
show that IL-5 acts in a similar way. Therefore, our findings indi-
cate that eosinophils from patients with atopic dermatitis are present 
in a "primed" form. Most likely this priming is caused by cytokines, 
such as IL-3, IL-5, and GM-CSF. Indeed, these cytokines are pro-
duced by activated lymphocytes in the circulation of asthma and 
patients with atopic dermatitis [15,16]. These findings therefore 
extend our recent findings on priming mechanisms in allergic 
asthma [22]. Also, in this allergic disorder the eosinophils are 
present in a primed state in the .circulation, which might be due to 
previous exposure to the cytokmes IL-3, IL-5, and GM-CSF [22]. 
Taken together, our findings extend existing it! vitro evidence that 
these cytokines may alter a variety ~f eosinophil responses [23-28] 
to the in vivo situation (e.g., allergIC asthma and atopic dermatitis 
[22]) . Moreover, it has also been. suggested that "pri~ed". eosino-
phils present at an ~xtravas.cular s~te may exert pa~hoblOloglc effects 
by responding eaSIly to stlmulatlOn by soluble Itgands and the re-
lease of toxic mediators [29]. 
Although the eosinophils from patients with atopic dermatitis are 
already in a "primed" state, they can be further potentiated by in 
vitro contact with IL-5. This suggests that the in vivo "priming" has 
not been complete. 
The eosinophil is not yet considered an important effector cell in 
atopic dermatitis; however, eosinophilia is regularly observed in 
active atopic dermatitis [1]. Furthermore, deposits of eosinophil-
derived mediators such as major basic protein have been reported in 
lesional atopic dermatitis skin [3]. Patients with atopic dermatitis 
with elevated circulating IgE levels and positive intracutaneous skin 
reactions to aeroallergens frequently show a positive patch-test reac-
tion to those allergens [4]. During such a patch-test reaction, which 
shows a macroscopic and microscopic resemblance to lesional atopic 
dermatitis skin [5,6], eosinophils not only infiltrate but are also 
activated, causing release of mediators. In earlier reports, we consid-
ered the above-mentioned patch-test reaction to aeroallergens in 
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Figure 2. IL-5 modulation of the PAF- and C5a-induced migration of 
eosinophils from patients with atopic dermatitis. Eosinophil migration 
toward dose ranges of PAF (A) and C5a (B) was measured with Geys' 
buffer as a control. Eosinophils were preincubated for 30 min at 37°C in 
the presence of buffer (II) or IL-5 (0) ([IL-5] = 10-9 M). The number of 
cells per 10 high-power fields (hpf) was determined. Mean values ± SD 
are presented for six to seven experiments. • Differed significantly from 
control values (p < 0.05; paired Student t test). 
patients with atopic dermatitis an in vivo model to study the patho-
genesis of atopic dermatitis [5]. In this model, IgE-bearing Langer-
hans cells, present in the epidermis and dermis, are considered to 
present allergen to T cells [30]. These T cells are activated, leading 
to T-cell proliferation and concomitant cytokine release. Recently, 
T cells have been cloned from these patch-test reactions, and it has 
been found that these cells are of the Th2 subtype [31], producing, 
among others, IL-4 and IL-5 but not IL-2 or interferon-y [32] . 
Therefore, T cells can, by the release ofIL-5, contribute to selective 
eosinophil mobilization; however, other cells present in allergic 
lesions (e.g., mast cells and endothelial cells) may be activated as 
well and can therefore also contribute to eosinophil recruitment. Of 
note, a similar reaction sequence seems to take place in the allergen-
induced late-phase skin reaction and the classical delayed-type hy-
persensitivity reaction [33]. Also, in the allergen-induced late-phase 
reaction in the skin, activated eosinophils are present in the tissue 
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[33,34]. The findings reported h~re with ~egar~ to IL-5 prim in? of 
eosinophils and the consecutive lllcrease III migratory responsive-
ness toward FMLP, NAF/IL-8, PAF, and PF4 may partly explain 
the increased infiltration capacity of eosinophils in the patch test 
reaction and the allergen-induced late-phase reaction. Which of the 
above-mentioned factors is most important in mobilizing the eosin-
ophils is not yet known because the local concentrations. of the 
chemotaxins are unknown. These soluble factors may also stimulate 
the extravasated eosinophils to release toxic mediators [29] . Another 
interesting possibility is that these tissue eosinophils may contribute 
to the allergic inflammatory reaction by the release of the above-
mentioned cytokines themselves. In this way, the eosinophil could 
amplify the inflammatory response [35]. 
Taken together, our findings indicate that eosinophils from pa-
tients with atopic dermatitis are present in a pre-activated state in 
the circulation. This is likely to be caused by contact with the 
cytokines IL-3,.IL-5, .and GM-CSF from act.ivated T c~lls. IL-5 is 
selective for eoslllophlis and may therefore be Important III modulat-
ing/inducing the migratory response of eosinophils toward a vari-
ety of chemotaxins formerly thought to be mainly important for 
neutrophil mobilization. 
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